Hostname: page-component-7bb8b95d7b-fmk2r Total loading time: 0 Render date: 2024-10-04T04:14:09.830Z Has data issue: false hasContentIssue false
  • English
  • Français

A comparison of rapid-acting intramuscular (IM) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation

Published online by Cambridge University Press:  16 April 2020

K.R. Reeves ,
R.H. Swift  and
E.P. Harrigan
K.R. Reeves
Affiliation:
Central Research Division, Pfizer Inc, Groton, CT06340, USA
R.H. Swift
Affiliation:
Central Research Division, Pfizer Inc, Groton, CT06340, USA
E.P. Harrigan
Affiliation:
Central Research Division, Pfizer Inc, Groton, CT06340, USA

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Symposia
Information
European Psychiatry , Volume 13 , Issue S4: Standards of psychiatry - 9th Congress of Association of European Psychiatrists , 1998 , pp. 303s - 304s
Copyright
Copyright © European Psychiatric Association 1998
Submit a response

Comments

No Comments have been published for this article.